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ABSTRACT
Objectives: To investigate geographic variation in
guideline-indicated treatments for non-ST-elevation
myocardial infarction (NSTEMI) in the English National
Health Service (NHS).
Design: Cohort study using registry data from the
Myocardial Ischaemia National Audit Project.
Setting: All Clinical Commissioning Groups (CCGs)
(n=211) in the English NHS.
Participants: 357 228 patients with NSTEMI between
1 January 2003 and 30 June 2013.
Main outcome measure: Proportion of eligible
NSTEMI who received all eligible guideline-indicated
treatments (optimal care) according to the date of
guideline publication.
Results: The proportion of NSTEMI who received
optimal care was low (48 257/357 228; 13.5%)
and varied between CCGs (median 12.8%, IQR
0.7–18.1%). The greatest geographic variation was for
aldosterone antagonists (16.7%, 0.0–40.0%) and least
for use of an ECG (96.7%, 92.5–98.7%). The highest
rates of care were for acute aspirin (median 92.8%, IQR
88.6–97.1%), and aspirin (90.1%, 85.1–93.3%) and
statins (86.4%, 82.3–91.2%) at hospital discharge. The
lowest rates were for smoking cessation advice (median
11.6%, IQR 8.7–16.6%), dietary advice (32.4%, 23.9–
41.7%) and the prescription of P2Y12 inhibitors (39.7%,
32.4–46.9%). After adjustment for case mix, nearly all
(99.6%) of the variation was due to between-hospital
differences (median 64.7%, IQR 57.4–70.0%; between-
hospital variance: 1.92, 95% CI 1.51 to 2.44; interclass
correlation 0.996, 95% CI 0.976 to 0.999).
Conclusions: Across the English NHS, the optimal use
of guideline-indicated treatments for NSTEMI was low.
Variation in the use of specific treatments for NSTEMI
was mostly explained by between-hospital differences in
care. Performance-based commissioning may increase
the use of NSTEMI treatments and, therefore, reduce
premature cardiovascular deaths.
Trial registration number: NCT02436187.
INTRODUCTION
Non-ST-elevation myocardial infarction
(NSTEMI) is a leading cause of emergency
hospitalisation in Europe and accounts for
over 50 000 National Health Service (NHS)
admissions per year.1–3 Mortality rates follow-
ing NSTEMI are high, worse than that for
ST-elevation myocardial infarction, and its
incidence (which is already higher than
STEMI)4 5 is increasing with an ageing and
multimorbid population.6 7 However, clinical
outcomes from NSTEMI may be improved
through the use of guideline-indicated treat-
ments including evidence-based pharmaco-
logical therapies and invasive coronary
procedures.8
While hospitals are the cornerstone of the
management of acute myocardial infarction,
for many countries, treatments are deter-
mined by the local contracting of specialist
services including that of ambulances, emer-
gency departments and acute cardiac care.
For the NHS of England, this is the
Strengths and limitations of this study
▪ This study evaluated care across a national
healthcare service and used a clinical registry
designed specifically to evaluate quality of
non-ST-elevation myocardial infarction (NSTEMI)
care.
▪ Advanced statistical techniques that allowed
high-resolution analysis of combinations of path-
ways of care according to their eligibility and
receipt were used.
▪ A detailed 10-year evaluation of receipt of care—
few other national data sets can offer.
▪ Myocardial Ischaemia National Audit Project
does not collect all cases of NSTEMI; thus,
results of underuse of care interventions maybe
underestimated.
▪ We used CCGs to investigate consistency in geo-
graphic unit performance over time, when they
only recently have replaced Primary Care Trusts
and may not have the same Cartesian
boundaries.
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responsibility of the 211 Clinical Commissioning Groups
(CCGs) who work in partnership with hospitals, via
Strategic Clinical Networks (SCNs) for National Institute
for Health and Care Excellence support for commission-
ing for NSTEMI.3
Our earlier work found evidence for variation within
and between the UK and Sweden in treatments and
30-day mortality from acute myocardial infarction.1 2 9
Such variation in cardiac services is estimated to cost the
NHS £184 million.10 We have also shown that the major-
ity of patients with acute myocardial infarction fail to
receive at least one guideline-indicated treatment and
that these missed opportunities were associated with car-
diovascular deaths.12 For NSTEMI—the most common
and vulnerable type of acute myocardial infarction—
information concerning variation in guideline-indicated
treatments is very limited.13–17 For the English NHS,
there are no reports of how NSTEMI treatments vary
according to CCGs, which leaves a gap in our knowledge
as to how and where to focus efforts on reducing prema-
ture death from cardiovascular disease. Therefore, we
used the UK heart attack register (Myocardial Ischaemia
National Audit Project, MINAP) to conduct a 10-year
study of the geographic variation in guideline-indicated
treatments for NSTEMI.
METHODS
Setting and design
We included all NHS hospitals (n=232) in England
which provided care for patients (n=357 228) aged over
18 years with NSTEMI between 1 January 2003 and 30
June 2013. The diagnosis of NSTEMI was based on
guidelines from the European Society of Cardiology
(ESC), American College of Cardiology and American
Heart Association and determined at local level by the
attending Consultant.18 For multiple admissions, we
used the earliest record. Patient-level data concerning
demographics, cardiovascular risk factors, medical
history and clinical characteristics at the time of hospital-
isation were extracted from MINAP, a comprehensive
registry of hospitalisations for acute coronary syndrome
in England and Wales, which was started in 2000 and is
now mandated by the Department of Health.19 Details
of MINAP have been described previously.11 The data
ﬂow for the derivation of the analytical cohort can be
seen in ﬁgure 1.
Patient involvement
No patients were involved in the design or implementa-
tion of the study. However, we involved a patient in the
interpretation of the research and the writing of the
research manuscript.
Quality of care
We mapped iterative ESC guidelines for the management
of NSTEMI and ESC Expert Consensus Documents to
MINAP data to identify 13 guideline-indicated treatments
as they became available over the study period.20–25 They
included: the recording of an ECG, acute provision of
aspirin, at hospital discharge the prescription of P2Y12
inhibitors, aspirin, β blockers among patients with left
ventricular systolic dysfunction, ACE inhibitors (ACEis)/
angiotensin receptor blockers (ARBs) among patients
with left ventricular systolic dysfunction, aldosterone
antagonists among patients with left ventricular dysfunc-
tion and either diabetes or heart failure without signiﬁ-
cant renal dysfunction, HMG-CoA reductase enzyme
inhibitors (statins), and the use of early invasive proce-
dures (coronary angiography), echocardiography,
smoking cessation advice, dietary advice and enrolment
into a cardiac rehabilitation programme.8 21 We assessed
the receipt of guideline-indicated treatments only for
patients who were deemed eligible for each treatment
according to the ESC guidelines.20 21 23–25 Patients were
also classiﬁed as ineligible if a treatment was contraindi-
cated, not indicated, not applicable, if the patient
declined treatment as recorded in MINAP or if the
patient was hospitalised prior to the time the treatment
was recommended by the guidelines. See online supple-
mentary tables S1 and ﬁgure S1 for information about
how the ESC guidelines for the management of NSTEMI
were mapped to MINAP data.
Geographic units
We mapped each patient’s treatment data, located by
eastings and northings supplied by MINAP, to the April
2015 Geographic Information System CCGs layers
(accessed from NHS England) and created choropleth
maps to show the distribution of receipt of guideline-
indicated treatments using ArcGIS V.10.2.2. We used class
intervals with equal cut-offs for categorisation.
Statistical analysis
We assessed the overall provision of guideline-indicated
treatment by constructing composite scores for each
patient. To do this, we divided the total number of treat-
ments received by a patient by the total number of treat-
ments that the patient was eligible for.26–28 Optimal care
was deﬁned as receiving all (up to 13) guideline-
indicated treatments for which patients were eligible. We
dichotomised the score as receipt of optimal care and
non-receipt of optimal care (suboptimal care).
Furthermore, the composite scores were categorised as
high receipt (>79%), intermediate (40 to ≤79%) and
low (≤40%) according to recognised cut-offs.29 30 For
optimal care and each of the 13 ESC guideline-indicated
treatments in turn, we calculated the proportion of
patients who received the treatment according to their
location in a geographic unit. For example, for aspirin,
this would be ‘did the patient, who was eligible to
receive and had no contraindications, receive aspirin?’
We used percentages to describe categorical variables
and means and SDs or medians, IQRs and ranges for
continuous normally distributed and non-normally dis-
tributed variables, respectively. We used Spearman’s
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correlation to assess the relationship between receipt of
care in the earlier years (2003–2004) and receipt of care
in the later years (2012–2013) by CCGs. We also repre-
sented temporal changes in optimal care among CCGs
using Google Charts and motion maps.
To quantify variation within and between the geo-
graphic units, we used a four-level hierarchical Poisson
model31 comprising patients nested within hospitals,
nested within CCGs and nested within SCNs. The
outcome (receipt of optimal care) was modelled as a
count variable with a conditional Poisson distribution
and all NSTEMI patients in the cohort as the exposure.
The model incorporated patient-speciﬁc characteristics
as ﬁxed effects including demographics (sex, Index of
Multiple Deprivation score and ethnicity), cardiovascular
risk factors (diabetes, hypercholesterolaemia, hyperten-
sion, smoking status, asthma/chronic obstructive pul-
monary disease (COPD) and family history of coronary
heart disease), cardiovascular history (previous myocar-
dial infarction, heart failure, percutaneous coronary
intervention, coronary artery bypass grafting, angina,
cerebrovascular disease and peripheral vascular disease)
and the mini-GRACE risk score for predicted 6-month
mortality.32 In addition, hospital, CCG and SCN random
effects were included in the model to allow for cluster-
ing of patients within these levels. The intercept pro-
vided each patient’s expected rate of guideline-indicated
treatments (with a log transformation), adjusted for case
mix. We used the interclass correlation (ICC) to quantify
the proportion of variation in guideline-indicated treat-
ments that was attributable to hospitals, CCGs and SCNs
after adjustment for patient-speciﬁc characteristics. All
analyses were performed using Stata V.13.
Excess deaths
Multilevel accelerated failure time models were used
to identify the association between missed guideline-
indicated treatments and time to all-cause mortality. All
models included a shared frailty term to account for
clustering of patients within hospitals. Models were
adjusted for case mix using the adjusted mini-GRACE
risk score32 and for baseline patient characteristics
including: previous history of myocardial infarction,
angina, diabetes, hypertension, peripheral vascular
disease, family history of coronary heart disease,
asthma/COPD, hypercholesterolaemia and coronary
revascularisation. Models were ﬁtted on imputed data
and estimates pooled over 10 imputations (see online
supplementary table S2). In order to determine the
potentially preventable deaths associated with subopti-
mal treatment for hospitals, the adjusted mortality risk
(see online supplementary table S3) obtained from the
multilevel accelerated failure time models was multiplied
by the corresponding mortality rates and proportions of
patients in the suboptimal treatment groups per hos-
pital. The product was then multiplied by the total
Figure 1 STROBE diagram of
the derivation of the analytical
cohort from the MINAP data set.
MINAP, Myocardial Ischaemia
National Audit Project; NSTEMI,
non-ST-segment elevation
myocardial infarction.
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number of NSTEMI between 2003 and 2013 for each
hospital (see online supplementary section 3).
RESULTS
Of 357 228 patients with NSTEMI (mean age 70.9 (SD
13.3) years), 63.1% (n=225 009) were men, the majority
(93.1%, n=301 312) were white, one-third had angina and
a quarter had previous myocardial infarction (table 1).
Over half (n=254 215, 71.2%) were previous or
current smokers, 48.9% (n=174 596) had hypertension,
21.1% (n=75 433) diabetes and 14.6% (n=52 030) had
asthma or COPD. Over 2% (n=7280) of patients had an
admission systolic blood pressure <90 mm Hg. About
half (n=184 631, 56.8%) of all electrocardiographic
changes were ST-segment deviation or T-wave inversion
with 15.7% (n=51 214) of patients having no acute
Table 1 Baseline characteristics, NSTEMI, 2003–2013
Characteristics
Cases
n=357 228 Missing
Age, years; mean (SD) 70.9 (13.3) 504 (0.1)
Male 225 009 (63.1) 593 (0.2)
Deprivation according to IMD score
1 (least deprived) 61 235 (17.2) 419 (0.1)
2 70 084 (19.6)
3 74 842 (21.0)
4 72 121 (20.2)
5 (most deprived) 78 527 (22.0)
Prior medical history
Myocardial infarction 89 571 (25.1) 0*
Heart failure 22 581 (6.3) 0*
PCI 30 835 (8.6) 0*
CABG 26 021 (7.3) 0*
Angina 113 059 (31.7) 0*
Cerebrovascular disease 31 366 (8.8) 0*
Peripheral vascular disease 16 868 (4.7) 0*
Diabetes 75 433 (21.1) 0*
Chronic renal failure 20 349 (5.7) 0*
Hypercholesterolaemia 112 713 (31.5) 0*
Hypertension 174 596 (48.9) 0*
Previous or current smoker 254 215 (71.2) 0*
Asthma or COPD 52 030 (14.6) 0*
Family history of CHD 72 444 (20.3) 0*
Presenting characteristics
Systolic blood pressure, mm Hg, mean (SD) 142.5 (28.4) 59 962 (16.8)
Systolic blood pressure, <90 mm Hg 7280 (2.5) 59 962 (16.8)
Heart rate, bpm, mean (SD) 80 (67–95) 59 177 (16.6)
Heart rate >110 bpm 32 964 (11.1) 59 177 (16.9)
Creatinine; mean (SD) 92 (76–114) 147 959 (41.4)
Troponin elevation 321 212 (94.6) 17 559 (4.9)
Cardiac arrest 6178 (1.8) 21 038 (5.9)
ECG
No acute changes 51 214 (15.7) 31 825 (8.9)
ST-segment elevation 14 336 (4.4)
Left bundle branch block 21 149 (6.5)
ST-segment depression 84 821 (26.1)
T-wave changes only 85 474 (26.3)
Other acute abnormality 68 409 (21.0)
Use of a loop diuretic 89 438 (30.2) 61 294 (17.1)
GRACE risk score category
Low (≤88) 25 787 (18.2) 215 599 (60.4)
Intermediate (88–110) 38 897 (27.5)
High (>110) 76 945 (54.3)
GRACE risk score category as defined by NICE.
*Missing data default imputed to ‘No’.
CABG, coronary artery bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; IMD, Index of Multiple
Deprivation; NICE, National Institute for Health and Care Excellence; NSTEMI, non-ST-segment elevation myocardial infarction; PCI,
percutaneous coronary intervention.
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changes. According to the mini-GRACE risk score, 8 in
10 patients were in intermediate or high risk. The distri-
bution of patients eligible to receive guideline-indicated
treatments is shown in table 2, the highest being for an
ECG and the lowest for smoking cessation advice.
Guideline-indicated interventions
The proportion of NSTEMI who received optimal care
was low (48 257/357 228, 13.5%). One in 10 (n=42 229,
11.8%) received ≤40% of the guideline-indicated treat-
ments for which they were eligible, 6 in 10 (n=208 930,
58.5%) received >40% to ≤79% and 3 in 10 (n=106 069,
29.7%) received >79%. The most frequently missed were
dietary advice (n=231 201, 67.4%), smoking cessation
advice (n=222 532, 87.5%), echocardiography
(n=178 344, 49.9%), P2Y12 inhibitors at discharge from
hospital (n=175 023, 59.0%), coronary angiography
(n=146 075, 42.6%) and in-hospital aspirin (n=97 411,
44.8%) (table 2). Over half of the patients (n=207 355,
58.1%) were not under the care of a cardiologist.
Geographic variation
For CCGs, the proportion of patients who received
optimal care was low (median 12.8%, IQR 0.7–18.1%)
(ﬁgure 2). The greatest variation in care was for aldoster-
one antagonists (median 16.7%, IQR 0.0–40.0%) and least
for use of an ECG (96.7%, 92.5–98.7%). High rates of the
prescription of aspirin acutely (median 92.8%, IQR
88.6–97.1%), aspirin at discharge from hospital (90.1%,
85.1–93.3%) and statins (86.4%, 82.3–91.2%) were consist-
ent. The provision of echocardiography (50.3%,
38.3–61.9%), cardiac rehabilitation (79.7%, 68.2–87.1%),
coronary angiography (57.4%, 48.8–66.7%), the prescrip-
tion of ACEis/ARBs (69.0%, 63.6–74.0%) and β blockers
(76.3%, 70.4–82.0%) was intermediate and varied widely,
while the provision of smoking cessation advice (11.6%,
8.7–16.6%), dietary advice (32.4%, 23.9–41.7%) and P2Y12
inhibitors (39.7%, 32.4–46.9%) was poor.
Across SCNs, the proportion of patients who received
optimal care was also low (median 12.2%, IQR 11.5–
15.9%) (see online supplementary table S4). The area
with the highest proportion of patients who received
optimal care was North East and North Cumbria (n=7045,
20.0%), and the lowest was the East Midlands (n=3409,
10.3%). Rates of guideline-indicated interventions were
intermediate-to-high and varied little between SCNs for
ECG (median 95.0%, IQR 92.0–96.0%), acute aspirin
(91.0%, 88.0–92.0%), statins (86.0%, 84.0–87.0%),
aspirin on discharge (89.0%, 87.0–90.0%), cardiac
rehabilitation (79.0, 72.0–82.0%), β blockers (76.0%,
73.0–76.0%) and the prescription of ACEis/ARBs
(68.0%, 67.0–70.0%). Performance was consistently low
across SCNs for P2Y12 inhibitors (40.0%, 39.0–42.0%),
aldosterone antagonists (27.0%, 20.0–28.0%), smoking
cessation advice (13.0%, 12.0–17.0%) and dietary advice
(32.0%, 28.0–37.0%). Echocardiography (50.0%, 45.0–
55.0%) and coronary angiography (58.0%, 52.0–61.0%)
were provided at an intermediate rate.
Variance components
The between-unit variance, standardised for case mix,
was low for SCNs (0.004, 95% CI 0.0004 to 0.03) and
CCGs (0.004, 0.001 to 0.03) but much higher for hospi-
tals (1.92, 95% CI 1.51 to 2.44). Moreover, the model
indicated that 0.2% of the remaining variation in the
provision of guideline-indicated care after case mix
adjustment was between SCNs (ICC 0.002, 95% CI
0.0002 to 0.01) and 0.2% between CCGs (ICC 0.002,
95% CI 0.0007 to 0.01) with 99.6% between hospitals
(ICC 0.996, 95% CI 0.976 to 0.999) (table 3). Hospital
variation in optimal care was consistently wide within
SCNs of differencing performance (ﬁgure 3).
Table 2 Eligibility and receipt of guideline-indicated interventions, NSTEMI, 2003–2013
Guideline-indicated
intervention
Number (%) of NSTEMI who
received a guideline-indicated
intervention
Number of NSTEMI eligible for
a guideline-indicated
intervention
ECG 336 094 (94.1) 357 228
Acute aspirin 212 837 (88.7) 239 876
Echocardiography 178 851 (50.1) 357 195
Coronary angiography 196 781 (57.4) 342 856
Aspirin at discharge 279 584 (89.1) 313 901
P2Y12 inhibitors 121 427 (41.0) 296 450
ACEis/ARBs 81 176 (67.9) 119 625
β Blockers 80 600 (74.8) 107 698
Statins at discharge 275 626 (86.2) 319 747
Aldosterone antagonists 134 (23.7) 566
Dietary advice 111 759 (32.6) 342 960
Smoking cessation advice 31 683 (12.5) 254 215
Cardiac rehabilitation 257 875 (76.7) 336 146
ACEis, ACE inhibitors; ARB, angiotensin receptor blockers.
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Temporal changes
Table 4 shows the improvement in the provision NSTEMI
care from 2003/2004 to 2012/2013, being most pro-
nounced for coronary angiography (median CCG rates:
33 vs 83%), ACEis/ARBs (71 vs 100%) and β blockers (77
vs 100%). Even so, there was only a modest improvement
in optimal care, and although the correlation between
care in CCGs over the study period was signiﬁcant, it was
weak (ρ=0.36, p<0.001). Temporal trends in the propor-
tion of NSTEMI who received guideline-indicated treat-
ments between 2003 and 2013 are shown in interactive
ﬁgures 4 and 5 which can be accessed by clicking on the
Figure 2 Geographic variation proportions of eligible patients who received guideline-indicated interventions, for each
intervention and for optimal care, by CCG. ACEis, ACE inhibitors; ARB, angiotensin receptor blockers; CCGs, Clinical
Commissioning Groups.
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following web links: http://www.personal.leeds.ac.uk/
~medcardp/googleplots.html and http://www.personal.
leeds.ac.uk/~medcardp/map.html respectively.
Excess deaths
Over the study period, the case mix standardised excess
mortality associated with non-receipt of optimal guideline-
indicated care varied between hospitals (median number
of deaths 39, IQR 15–62) between 2003 and 2013.
DISCUSSION
Over a 10-year study period, we found evidence for wide-
spread suboptimal use of guideline-indicated treatments
for the management of NSTEMI. While the use of spe-
ciﬁc treatments for NSTEMI, such as pharmacological
Table 3 Parameter estimates, p values, SEs and 95% CIs for optimal receipt of care for the Poisson model
Fixed effects Incidence ratios p Value 95% CI
Sex (male vs female) 1.12 <0.001 1.11 to 1.15
Deprivation according to IMD score
1 (least deprived) 1 – 1
2 0.98 0.34 0.95 to 1.02
3 0.99 0.41 0.95 to 1.02
4 0.97 0.06 0.93 to 1.00
5 (most deprived) 0.96 0.02 0.92 to 0.99
Ethnicity
White 1 – 1
Black 0.99 0.78 0.90 to 1.08
Asian 1.02 0.32 0.98 to 1.07
Mixed 1.21 0.07 0.98 to 1.48
Other 0.92 0.10 0.84 to 1.02
GRACE risk score category
Low (≤88) 1 – 1
Intermediate (88–110) 0.97 0.16 0.94 to 1.01
High (>110) 0.78 <0.001 0.76 to 0.81
Current smoker (Yes vs No) 1.16 <0.001 1.14 to 1.19
Prior diabetes (Yes vs No) 0.99 0.88 0.98 to 1.02
Prior MI (Yes vs No) 0.90 <0.001 0.88 to 0.92
Prior angina (Yes vs No) 0.91 <0.001 0.89 to 0.93
Prior PCI (Yes vs No) 0.98 0.33 0.95 to 1.02
Prior CABG (Yes vs No) 0.95 0.01 0.92 to 0.99
Prior peripheral vascular disease (Yes vs No) 0.95 0.03 0.91 to 0.99
Hypercholesterolemia 1.11 <0.001 1.08 to 1.13
Prior hypertension (Yes vs No) 1.02 0.08 1.00 to 1.04
Prior cerebrovascular disease (Yes vs No) 0.88 <0.001 0.84 to 0.90
Prior chronic obstructive pulmonary disease/asthma (Yes vs No) 0.94 <0.001 0.92 to 0.97
Family history of CHD (Yes vs No) 1.15 <0.001 1.13 to 1.17
Year 1.60 <0.001 1.60 to 1.62
Random effects Variance Standard error 95% CI
Hospital variance
1.92 0.24 1.51 to 2.44
CCG variance
0.004 0.004 0.001 to 0.03
SCN variance
0.004 0.004 0.0004 to 0.03
CABG, coronary artery bypass graft; Clinical Commissioning Groups (CCGs); CHD, coronary heart disease; COPD, chronic obstructive
pulmonary disease; IMD, Index of multiple deprivation; PCI, percutaneous coronary intervention; Strategic Clinical Networks (SCNs).
Figure 3 Optimal care variation in hospitals by SCNs.
SCNs, Strategic Clinical Networks.
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therapies and invasive coronary procedures, varied
between CCGs, most of the variation (after accounting
for differences in patients) was explained by differences
in the provision of care by hospitals. We found that the
geographical variation in NSTEMI treatments was asso-
ciated with geographical variation in the number of
excess deaths. Together, the ﬁndings from our study
suggest that there is substantial scope to improve the pro-
vision and uniformity of NSTEMI care across the NHS
and, therefore, reduce premature cardiovascular death.
In contrast to recent reports of geographic and tem-
poral variation in the inappropriate use of cardiac proce-
dures,33 we found that many patients who were eligible
to receive care did not. The greatest variation was for
the prescription of aldosterone antagonists and least for
use of an ECG. Speciﬁcally, when we deﬁned care using
a composite score according to eligibility for any of the
13 international guideline recommended treatments
and according to the date from which they were pub-
lished, we found that optimal care was delivered infre-
quently. Even though we found that optimal care varied
geographically, it was only when we evaluated speciﬁc
interventions that we found much wider variations in
care. This was evidenced by wide variation in the provi-
sion of key interventions such as coronary angiography,
cardiac rehabilitation and pharmacological therapies.
After adjustment for case mix, most of the variation in
NSTEMI care occurred at the level of the hospital and
to a much lesser extent between CCGs and SCNs. This
ﬁnding is not surprising because hospitals are the
service providers for the treatment of NSTEMI. Our
earlier research has described the missed opportunities
for care among patients who present to NHS hospitals
with acute myocardial infarction and that this was signiﬁ-
cantly associated with reduced survival.11,13 We have also
shown that between-hospital variation in care is wider in
the UK than in Sweden, and this was also associated with
a higher and wider range of mortality rates in the UK.2
For this study, we elected to investigate geographic vari-
ation in care according to CCGs rather than hospitals
because CCGs are central to the contracting of NSTEMI
services and to whom hospitals are ﬁnancially accountable.
Causes of healthcare variation are numerous and
complex. They may be due to differences in patterns of
illness, clinicians’ behaviour or the effects of incentives
in the ﬁnancing of healthcare.34 35 In this study, we
found that variation in the provision of NSTEMI treat-
ment remained after adjusting for patient sociodemo-
graphic and clinical characteristics. This suggests that
modiﬁable factors such as procurement, infrastructure,
availability of specialist services and physician education
are critical.34 Typically the use and availability of cardiac
procedures are closely related.15 36 However, this is not
always the case and it is possible that other factors
are also at play such as physician-dependent risk-aversion
to invasive cardiac care,37 a perception that higher risk
patients do not have a net beneﬁt from NSTEMI care,
difﬁculties in obtaining an early and accurate diagnosis
of NSTEMI,38 39 the availability of specialist cardiac,
emergency and ambulance services staff, size and type of
acute hospital40 as well as the placement patients with
NSTEMI on adequately staffed specialist wards within
a hospital.37 In addition, we found little evidence to
suggest that the performance of a geographic unit
remained constant (though overall there was improve-
ment in care over time). Our ﬁndings suggest that
regional networks of care for NSTEMI are immature
and can be compared with the provision of STEMI care
in the UK where there is institutional (and regional)
operationalisation effecting high-quality care and low
mortality rates.40 41
Ours and others’ previous work have demonstrated
signiﬁcant associations between adherence to evidence-
based care for the management of NSTEMI and better
clinical outcomes.11 26 42 Data from the CRUSADE regis-
try have also shown that patients with NSTEMI who
receive guideline-indicated care have better outcomes
and that this is associated with the type of hospital to
which a patient is admitted.13 43 Even though our
research concentrated mainly the evaluation of pro-
cesses of care, we also found that there was variation
between hospitals in the numbers of potentially avoid-
able deaths. This is not a surprising ﬁnding because our
study was of guideline-indicated treatments endorsed by
international societies with mostly Class 1A recommen-
dations that have been shown in randomised studies to
improve clinical outcomes.8 44 Tackling inequalities in
Table 4 Temporal changes in the proportion of NSTEMI
receiving guideline-indicated treatments, 2003/2004 vs
2012/2013 in CCGs
Guideline-indicated
intervention
Biennial year
2003/2004
Median (IQR)
2012/2013
Median (IQR)
Optimal care 0.00 0.34 (0.23–0.46)
ECG 0.86 (0.69–0.96) 1.00 (0.99–1.00)
Acute aspirin 0.88 (0.81–0.94) 0.97 (0.93–0.99)
ACEis/ARBs 0.71 (0.65–0.76) 1.00 (1.00–1.00)
β Blockers 0.77 (0.71–0.83) 1.00 (0.93–1.00)
Statins 0.83 (0.77–0.88) 0.95 (0.91–0.98)
P2Y12 inhibitors 0.00 0.94 (0.88–0.98)
Aldosterone
antagonist
– 0.00 (0.00–1.00)
Echocardiography 0.41 (0.27–0.57) 0.63 (0.51–0.76)
Cardiac rehabilitation 0.73 (0.60–0.83) 0.87 (0.74–0.94)
Smoking cessation
advice
0.00 0.69 (0.47–0.87)
Dietary advice 0.00 0.84 (0.62–0.93)
Coronary
angiography
0.33 (0.21–0.47) 0.83 (0.75–0.89)
Aspirin on discharge 0.89 (0.83–0.93) 0.97 (0.94–0.99)
Median represents the median of the proportion of eligible
NSTEMI who received guideline-indicated care.
ACEis, ACE inhibitors; ARB, angiotensin receptor blockers;
CCGs, Clinical Commissioning Groups; NSTEMI,
non-ST-segment elevation myocardial infarction.
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care at the level of the healthcare professional, service
provider and commissioner will lead to a reduction in
the numbers of deaths from NSTEMI.
By representing processes of clinical care at the level
of the CCG, commissioners may identify where and what
service may require closer attention. Moreover, it is plaus-
ible that the introduction of a performance-based tariff
for NSTEMI (or an additional best practice payment)45
may improve outcomes and reduce provider variation.
This is because others have reported associations between
performance-based commissioning and improved quality
of care and outcomes, albeit not for NSTEMI.46–49 For
example, the introduction of the Advancing Quality pro-
gramme across all NHS hospitals in the north-west of
England was associated with a signiﬁcant reduction in
combined short-term mortality for pneumonia, heart
failure and acute myocardial infarction.49
Our study has strengths in that it evaluated care across
a national healthcare service and accesses a clinical
registry designed speciﬁcally to evaluate quality of
NSTEMI care. Even though variance in adherence to
guideline-indicated care for NSTEMI has been reported
by others,50 51 it has not been evaluated across a single
healthcare system—which should, therefore, vary to a
lesser degree than across different health systems operat-
ing in one country. In this study, we undertook a system-
atic approach to evaluate variation in care.52 First, we
quantiﬁed variability in rates across different layers of
geographic units. Second, we calculated indexes, includ-
ing the systematic component of variation. Third, we
developed explanations for the variation by adjusting for
case mix. In addition to the main ﬁndings, our study is
an example of how patient-level clinical registries allow
higher resolution interrogation of pathways of care,53
the results of which should stimulate bespoke quality
improvement tailored to region and intervention.
Our study, however, has limitations. MINAP does not
collect all cases of NSTEMI—even so, our study was
designed to study the impact of missed care at the level
of the patient and not the numbers of NSTEMI hospita-
lised. We speculate that MINAP captures less than half
of all NSTEMI; consequently, the number of missed
opportunities that we report will be underestimated.
Conversely, it is possible that some patients will have
received treatments, but this not recorded in MINAP. We
used CCGs to investigate consistency in geographic unit
performance over time, when they only recently have
replaced Primary Care Trusts and may not have the
same Cartesian boundaries. The deﬁcits in care for
smoking cessation and dietary advice may be artiﬁcially
inﬂated because advice about smoking and diet are
implicit in cardiac rehabilitation programmes and there
may have been preferencing by coders towards record-
ing cardiac rehabilitation.
In conclusion, this study found that between 2003 and
2013, most of the 357 228 patients hospitalised with
NSTEMI did not receive optimal international
guideline-indicated care, although this ﬁnding was less
evident in the latter years of study. Receipt of optimal
care for the management of NSTEM, and more so the
individual components of the NSTEMI treatment
pathway, varied widely by hospitals across the English
NHS and was associated with between-hospital variation
in excess deaths. Given adherence to guideline-indicated
care for the management of NSTEMI is associated with
improved clinical outcomes, addressing the provision of
care through performance-based commissioning and
stronger networks of NSTEMI care has the potential to
reduce premature deaths from cardiovascular disease.
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